MarketCap
Facebook
X
TelegramQuarterly report 2023-Q3
added 11-14-2023
Adamis Pharmaceuticals Corporation Revenue 2011-2026 | ADMP
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Adamis Pharmaceuticals Corporation
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 4.76 M | 2.21 M | 16.5 M | 22.1 M | 15.1 M | 13.1 M | 6.47 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 22.1 M | 2.21 M | 11.5 M |
Quarterly Revenue Adamis Pharmaceuticals Corporation
| 2023-Q3 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9.06 K | 1.45 M | - | 1.51 M | 39.8 K | 1.15 M | - | 760 K | 1.28 M | 1.39 M | - | 868 K | 3.93 M | 4.66 M | - | 5.9 M | 5.76 M | 4.91 M | - | 3.83 M | 3.92 M | 3.18 M | - | 3.39 M | 3.81 M | 3.04 M | - | 2.08 M | 1.93 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 5.9 M | 9.06 K | 2.67 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Drug manufacturers industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AcelRx Pharmaceuticals
ACRX
|
28 K | - | 7.5 % | $ 6.35 M |  USA |
 |
Aerie Pharmaceuticals
AERI
|
194 M | - | - | $ 754 M | USA |
 |
Agile Therapeutics
AGRX
|
19.6 M | - | 10.11 % | $ 58.2 M | USA |
 |
Cronos Group
CRON
|
46.7 M | $ 2.68 | -0.19 % | $ 1.36 B |  Canada |
 |
Cumberland Pharmaceuticals
CPIX
|
10.4 M | $ 4.13 | 1.72 % | $ 58.1 M | USA |
 |
Catalent
CTLT
|
4.38 B | - | - | $ 11.5 B | USA |
 |
Alimera Sciences
ALIM
|
80.8 M | - | - | $ 142 M | USA |
 |
Athenex
ATNX
|
103 M | - | -23.39 % | $ 1.76 M | USA |
 |
DURECT Corporation
DRRX
|
8.55 M | - | - | $ 50.1 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
317 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
2.01 B | - | - | $ 28.9 M |  Irlanda |
 |
Avadel Pharmaceuticals plc
AVDL
|
169 M | - | - | $ 2.06 B |  France |
 |
Evoke Pharma
EVOK
|
5.18 M | - | - | $ 36.6 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
874 K | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
191 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Bausch Health Companies
BHC
|
8.76 B | $ 5.66 | 0.62 % | $ 2.07 B | Canada |
 |
Jupiter Wellness
JUPW
|
2.12 M | - | - | $ 33.6 M | USA |
 |
Canopy Growth Corporation
CGC
|
269 M | $ 1.19 | - | $ 128 M | Canada |
 |
Harrow Health
HROW
|
272 M | $ 41.22 | 3.82 % | $ 1.52 B | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
14.3 M | $ 1.09 | -4.82 % | $ 1.35 M | USA |
 |
Lannett Company
LCI
|
341 M | - | 1.15 % | $ 7.11 M | USA |
 |
Tilray
TLRY
|
627 M | $ 6.77 | 0.3 % | $ 4.18 B | Canada |
 |
OrganiGram Holdings
OGI
|
160 M | $ 1.43 | -1.04 % | $ 402 M | Canada |
 |
Organogenesis Holdings
ORGO
|
482 M | $ 2.38 | 1.49 % | $ 313 M | USA |
 |
Evolus
EOLS
|
297 M | $ 5.29 | -0.28 % | $ 341 M | USA |
 |
Sundial Growers
SNDL
|
946 M | $ 1.52 | 0.33 % | $ 3.37 M | Canada |
 |
Veru
VERU
|
16.9 M | $ 2.35 | 1.15 % | $ 317 M | USA |
 |
Emergent BioSolutions
EBS
|
1.05 B | $ 8.03 | 0.06 % | $ 411 M | USA |
 |
Pacira BioSciences
PCRX
|
542 M | $ 25.13 | 2.53 % | $ 1.16 B | USA |
 |
Viatris
VTRS
|
15.4 B | $ 14.75 | 1.06 % | $ 17.7 B | USA |
 |
Neoleukin Therapeutics
NLTX
|
925 K | - | - | $ 193 M | Canada |
 |
ProPhase Labs
PRPH
|
123 M | - | - | $ 5.07 M | USA |
 |
cbdMD
YCBD
|
19.5 M | $ 0.94 | -6.2 % | $ 4.05 M | USA |
 |
Radius Health
RDUS
|
230 M | - | - | $ 1.42 B | USA |
 |
Assertio Holdings
ASRT
|
119 M | $ 18.07 | 0.17 % | $ 116 M | USA |
 |
PetIQ
PETQ
|
1.1 B | - | 1.64 % | $ 400 M | USA |
 |
Relmada Therapeutics
RLMD
|
5.13 K | $ 7.01 | -2.84 % | $ 277 M | USA |
 |
Recro Pharma
REPH
|
94.6 M | - | -4.76 % | $ 65.3 M | USA |
 |
OptiNose
OPTN
|
71 M | - | - | $ 1.08 B | USA |
 |
SCYNEXIS
SCYX
|
20.6 M | $ 1.02 | - | $ 50.9 M | USA |
 |
PLx Pharma
PLXP
|
8.21 M | - | -27.8 % | $ 2.56 M | USA |
 |
Aurora Cannabis
ACB
|
175 M | $ 3.46 | 1.92 % | $ 86.3 M | Canada |
 |
Zomedica Corp.
ZOM
|
32 M | - | -0.21 % | $ 98 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
86 K | - | - | $ 55.5 M | USA |
 |
Rockwell Medical
RMTI
|
69.3 M | $ 0.84 | -3.38 % | $ 30.2 M | USA |
 |
China Pharma Holdings
CPHI
|
4.14 M | $ 0.59 | -2.97 % | $ 2.53 M |  China |
 |
TherapeuticsMD
TXMD
|
3.02 M | $ 2.17 | -0.91 % | $ 25.1 M | USA |